Search alternatives:
significant treatment » significant investment (Expand Search), significant enrichment (Expand Search), significant impairment (Expand Search)
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
treatment decrease » treatment decreased (Expand Search), treatments decreased (Expand Search), treatment increases (Expand Search)
significant treatment » significant investment (Expand Search), significant enrichment (Expand Search), significant impairment (Expand Search)
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
treatment decrease » treatment decreased (Expand Search), treatments decreased (Expand Search), treatment increases (Expand Search)
-
1641
Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms
Published 2025“…Postmenopausal osteoporosis (PMO) is characterized by an imbalance in bone remodeling with increased osteoclast and decreased osteoblast activity, leading to bone loss and higher fracture risk. …”
-
1642
Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms
Published 2025“…Postmenopausal osteoporosis (PMO) is characterized by an imbalance in bone remodeling with increased osteoclast and decreased osteoblast activity, leading to bone loss and higher fracture risk. …”
-
1643
Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms
Published 2025“…Postmenopausal osteoporosis (PMO) is characterized by an imbalance in bone remodeling with increased osteoclast and decreased osteoblast activity, leading to bone loss and higher fracture risk. …”
-
1644
-
1645
-
1646
-
1647
-
1648
-
1649
-
1650
-
1651
-
1652
-
1653
-
1654
-
1655
Synthesis and Biological Evaluation of MEK/mTOR Multifunctional Inhibitors as Novel Anticancer Agents
Published 2025“…Additionally, compound LP-65 demonstrated significant modulation of MEK and mTOR signaling activity in human glioma cells (D54) and human melanoma cells (A375), with a corresponding decrease in cellular proliferation and migration. …”
-
1656
-
1657
-
1658
-
1659
-
1660